News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PLC Systems, Inc. to Demonstrate RenalGuard® at EuroPCR 2012



5/14/2012 10:08:30 AM

MILFORD, Mass., May 11, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced it will demonstrate its innovative product, RenalGuard®, at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). More than 11,000 clinicians and medical professionals from around the world are expected to attend this event in Paris, France from May 15 18, 2012.

In addition, RenalGuard Therapy® has been selected to be presented as part of EuroPCR's Cardiovascular Innovation Pipeline and will be featured in a poster to be displayed throughout the conference. The poster, RenalGuard - an old idea with a modern twist: preventing contrast induced nephropathy through induced diuresis with matched replacement, describes the issues around Contrast-Induced Nephropathy (CIN), the theory behind RenalGuard Therapy, and the recent clinical trials demonstrating the efficacy of RenalGuard in reducing the incidence of CIN in interventional procedures utilizing contrast. The poster is available at PLC's website, http://plcmed.com/Educational-Resources-White-Papers-and-Abstracts23.asp.

PLC will also be hosting a meeting of international distributors and leading practitioners to showcase RenalGuard as a 'best practice' in the field and help galvanize international sales and marketing efforts.

About PLC Systems

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.

Contact:

Mary T. Conway


508-520-2545


mconway@plcmed.com

SOURCE PLC Systems Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES